Literature DB >> 35217910

Metabolic syndrome in childhood cancer survivors: delta BMI a risk factor in lower-middle-income countries.

Arushi Agarwal1, Gauri Kapoor2, Sandeep Jain1, Payal Malhotra1, Anurag Sharma3.   

Abstract

PURPOSE: Metabolic syndrome (MetSyn) is an important late effect of childhood cancer. The combination of rising obesity and high prevalence of under-nutrition at diagnosis makes this a unique population to study in LMIC (lower middle-income countries).
METHODS: Children ≤ 18 years of age at cancer diagnosis, in a single center in a LMIC, who were disease free and had completed treatment at least 2 years prior to study were included. MetSyn was defined using International Federation for Diabetes criteria for Asian Indians. Logistic regression analyses were carried out to evaluate the influence of various risk factors, including delta BMI (increase in body mass index from diagnosis to evaluation), on MetSyn.
RESULTS: A high prevalence of MetSyn (12.2%), central obesity (33%), and dyslipidemia (61.8%) were found in a cohort of 500 Asian Indian childhood cancer survivors (CCS) at a median follow-up age of 17 years. Multivariable analysis revealed older age at diagnosis ≥ 10 years, OR 2.9 (1.6-5); longer survival duration ≥ 10 years, OR 2.2 (1.3-3.8); high BMI at diagnosis, OR 3.2 (1.5-6.9); and large delta BMI ≥ 50, OR 3.15(1.7-5.9) to be independent predictors of MetSyn. Patients who were underweight or normal at diagnosis with large delta BMI ≥ 50 had very high odds (OR, 12.5, 1.7-92) of developing MetSyn compared to those with lower delta BMI. CONCLUSIONS AND IMPLICATIONS FOR CANCER SURVIVORS: A high prevalence of MetSyn was observed in CCS with early age at onset. Timely screening and early intervention are proven to be beneficial and delta BMI could be a useful screening tool for LMIC.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Childhood cancer survivors; Delta BMI; Late effects; Metabolic syndrome

Mesh:

Year:  2022        PMID: 35217910     DOI: 10.1007/s00520-022-06910-0

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  7 in total

1.  The metabolic syndrome in children and adolescents.

Authors:  Paul Zimmet; George Alberti; Francine Kaufman; Naoko Tajima; Martin Silink; Silva Arslanian; Gary Wong; Peter Bennett; Jonathan Shaw; Sonia Caprio
Journal:  Lancet       Date:  2007-06-23       Impact factor: 79.321

2.  Components of the metabolic syndrome in 500 adult long-term survivors of childhood cancer.

Authors:  M van Waas; S J C M M Neggers; R Pieters; M M van den Heuvel-Eibrink
Journal:  Ann Oncol       Date:  2009-10-22       Impact factor: 32.976

Review 3.  Obesity in Low- and Middle-Income Countries: Burden, Drivers, and Emerging Challenges.

Authors:  Nicole D Ford; Shivani A Patel; K M Venkat Narayan
Journal:  Annu Rev Public Health       Date:  2016-12-23       Impact factor: 21.981

4.  Absolute Lymphocyte Count Recovery Independently Predicts Outcome in Childhood Acute Lymphoblastic Leukemia: Experience From a Tertiary Care Cancer Center of a Developing Country.

Authors:  Anshul Gupta; Gauri Kapoor; Sandeep Jain; Ram Bajpai
Journal:  J Pediatr Hematol Oncol       Date:  2015-04       Impact factor: 1.289

Review 5.  Childhood obesity in Asian Indians: a burgeoning cause of insulin resistance, diabetes and sub-clinical inflammation.

Authors:  Swati Bhardwaj; Anoop Misra; Lokesh Khurana; Seema Gulati; Priyali Shah; Naval K Vikram
Journal:  Asia Pac J Clin Nutr       Date:  2008       Impact factor: 1.662

6.  Metabolic Health in Childhood Cancer Survivors: A Longitudinal Study in a Long-Term Follow-Up Clinic.

Authors:  Harriet M Gunn; Hanna Emilsson; Melissa Gabriel; Ann M Maguire; Katharine S Steinbeck
Journal:  J Adolesc Young Adult Oncol       Date:  2015-12-08       Impact factor: 2.223

7.  What is driving global obesity trends? Globalization or "modernization"?

Authors:  Ashley Fox; Wenhui Feng; Victor Asal
Journal:  Global Health       Date:  2019-04-27       Impact factor: 4.185

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.